Avidity Partners Management

Avidity's nine-office structure — spanning US hubs like San Francisco, Boston, and Baltimore, along with international locations in Tel Aviv, Toronto, and London — is designed to provide proximity to regional innovation clusters. This distributed research model gives the team access to academic key opinion leaders, clinical investigators, and biotech management teams across multiple geographies. The firm's sourcing relies on primary scientific diligence and direct engagement rather than relying solely on sell-side research or conference-driven idea generation.

Avidity focuses on publicly traded biopharma companies across therapeutic areas including oncology, rare disease, immunology, and genetic medicine. Public filings show the firm has held positions in names such as Revolution Medicines and Argenx across reporting periods. The strategy spans clinical-stage companies approaching binary catalysts and commercial-stage firms where market expectations diverge from fundamental revenue trajectories.

Avidity is headquartered in New York but operates a distributed footprint with offices in Dallas, Palo Alto, San Francisco, Boston, Baltimore, Miami, Toronto, London, and Tel Aviv. This multi-node model is unusual among biotech hedge funds and reflects a thesis that local presence in multiple innovation ecosystems improves access to management teams and scientific intelligence.